Conduit's new lab opening is a strategic move for portfolio expansion, enhanced development capabilities, and intellectual property growth. The company expects streamlined operations and improved clinical trial monitoring.
SpyderCall :
There is no news or any catalyst that I can find. The market is trying to bait new investors. Maybe news will drop soon but no reason to buy now
コンジット ファーマシューティカルズに関するコメント
まだコメントはありません